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Abstract
Plasmodium falciparum is main causative agent of malaria, a disease that affects half of world’s population. The
parasite’s dependence on glycolysis makes this pathway a suitable target for drug development. Understanding
the structure-function dynamics of glycolytic enzymes in different species has an important impact on the
development of selective drug analogues. Parasitic resistance and drug side effects of current antimalarial
drugs have complicated and increased the cost of curing malaria.
Molecular docking was used to explore structural motifs responsible for the interactions between triose
phosphate isomerase (TIM) from Plasmodium falciparum (PFTIM) and human (HTIM) tissues. Fourteen
antimalarial drugs were examined. The binding affinities and domains identified serve as a basis for modeling
novel analogues.
For all drugs modeled, PFTIM complexes displayed stronger binding affinities compared to HTIM. A
dissociation constant (KI) of 40.2 mM was obtained for the interaction between primaquine and HTIM and
1.22 mM with PFTIM. This represents a 33-fold increase in selective binding to PFTM compared to HTIM.
Mefloquine shows a 24-fold increase, and one new test ligand showed 25-fold increase in binding.
The dimer interface and other pocket close to the active site are the main pockets observed by the docking
studies. Key residues at the dimer interphase (Y48, D49, V46, S45, E65, S211) form a tight pocket with
favorable polar contacts. 75% of PFTIM ligand complexes preferred the dimer interphase suggesting a
potential site for non-competitive inhibition. These data suggest that TIM is a candidate for development of
antimalarial drugs.
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INTRODUCTION 
 
Parasitic organisms, such as 
plasmodium with a fully compartmentalized 
glycolytic pathway, are responsible for the 
world scourge (malaria) prevalent in tropical 
and subtropical regions of the world (Kehr 
et al., 2010). Malaria if untreated can lead to 
very debilitating conditions such as coma, 
brain damage, loss of muscle function and 
death (Bloland, 2001). Global mapping data 
estimates that about 3.2 billion people are at 
risk of contracting malaria every year 
(Guerra et al., 2006).   
The plasmodium parasite’s sole 
dependence on glycolysis for energy needs 
makes the pathway enzymes potential 
targets for antimalarial chemotherapies. 
(Sameer et al., 1997; Kim et al., 2005; 
Verlinde et al., 2001).  The decrease in 
efficiency of current antimalarial agents in 
many affected regions of the world due to 
toxic side effects, parasitic resistance and 
mutation has significantly increased the cost 
and complexity of curing malaria (Peterson 
et al., 2011; Bray et al., 2003; Briolant et al., 
2010). The limited number of antimalarial 
drugs, and parasitic resistance to almost 
every available chemical therapy continues 
to spur the search for novel, cheaper and 
better analogues (Plowe et al., 2007; Tony et 
al., 1997).  The molecular mechanism of 
how some antimalarial drugs exert their 
antimalarial activity is not completely 
understood. 
The differences in the way 
triosephosphate isomerase (TIM), in human 
cells (HTIM) and plasmodium cells 
(PFTIM) interact with 14 common 
antimalarial agents were explored. We 
postulate that this can serve as basis for 
developing novel analogues.  The increased 
application of Computer Aided Drug Design 
(CADD) methods in pharmaceutical 
industry and academia is a direct result of 
increase in computer speed, and the 
reliability of simulation theories and 
docking software (Schneider et al., 2002; 
Seeliger et al., 2010). 
TIM is a key dimeric enzyme that 
speeds up the final investment phase of 
glycolysis (Scheme 1). 
 
Scheme 1: Isomerization of DHAP and G3P by TIM 
 
HTIM and PFTIM share an amino acid 
sequence identity of 42 %.  Despite the 58 % 
difference in sequence identity, both 
molecules have similar structural folds. A 
root mean square deviation (RMSD) of 
0.825 Å is obtained when both enzymes are 
structurally aligned (Figure 1). HTIM and 
PFTIM do, however, have some amino acid 
residues located in key binding motifs with 
different side chain polarities (Figure 1).  
Position 96 that is close to TIM active site 
residues (K12, H95 and E165) in many TIM 
sequences is usually occupied by serine 
residue (Ser), but it is replaced by 
Phenylalanine (Phe) in PFTIM sequence. 
(Parthasarathy et al., 2002).  One goal of this 
study is to determine whether such 
differences and other unique structural 
motifs are critical for the selectivity of 
interactions between HTIM and PFTIM 
enzyme receptors.  
The molecular modeling software 
AutoDock 4.2 was used to screen the 
interactions of some antimalarial agents and 
as a tool to fine-tune analogues. The docking 
was also used to map different binding 
pockets and determine residues involved in 
complexes formed by HTIM and PFTIM.  
Furthermore, the binding affinities and 
dissociation constants of antimalarial agents 
and analogues are compared to determine 
what ligand features enhance selective 
affinity to TIM. 
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Figure 1: HTIM (green) and PFTIM (cyan) structures aligned. Key variant residues highlighted. HTIM-Yellow 
(A46, I48, S96) and PFTIM red (V46, Y48, F96). Active site residues (K12, H95 and E165) in Blue.
 
MOLECULAR SYSTEMS AND 
COMPUTATIONAL METHODS 
 
The X-ray crystal structures of 
HTIM and PFTIM have been determined to 
atomic resolution and were downloaded 
from the RCSB Protein Data Bank (Berman 
et al., 2000), with accession codes 4POC 
(Roland et al., 2015) and 2VFI respectively 
(Gayathri et al, 2009).  The molecular 
modeling software pymol (Delano, 2002) 
and chimera (Petterson et al., 2004) were 
used to refine the TIM three-dimensional 
structures prior to docking and create ligand 
protein complex figures. 
AutoDock 4.2 has been successfully 
used to predict the binding affinities and 
conformations between a number of ligands 
and molecular targets (Morris et al., 2009). 
In this study, antimalarial drugs were 
docked to HTIM and PFTIM (Table 1). The 
three-dimensional structures of the ligands 
were obtained from ligand databases 
DrugBank (Law et al., 2014) and Ligand 
explorer site (Moreland et al., 2005; Berman 
et al., 2000). The AutoDockTools suite was 
used to prepare the ligand and receptor 
structures, add appropriate Gasteiger 
charges, identify and modify ligand rotatable 
bonds (Morris et al., 2009). 
 
 
 
 
The ligands were then blindly docked into 
the rigid HTIM and PFTIM enzyme receptor 
using AutoDock 4.2.  A grid-based method 
was used to enhance the quick evaluation of 
the binding energy of conformations of the 
complexes formed.  The grid boxes were 
centered using coordinates of a virtual center 
of mass atom for PFTIM and HTIM.  The 
grid box had dimensions of 120 Å x 120 Å x 
120 Å, large enough to allow for sampling 
of binding domains or pockets on the entire 
protein surface by the probe ligand atoms. 
The Lamarckian genetic algorithm (Morris, 
1998) was used in configuration space 
search and determination binding energy of 
the complexes. The interaction affinity and 
selectivity of the docked complexes with the 
enzymes was evaluated using relative 
binding energies (Equation 1) and 
dissociation constants (Ki, Equation 2). The 
energetics of the binding process was 
estimated using pair-wise terms based on the 
semiempirical force field expression 
described in Equation 1 (Huey, 2006). The 
first term evaluates the 6/12 Lennard Jones 
potential (dispersion and repulsion 
interactions). The second term is a 
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directional hydrogen bond based potential 
term (Goodford, 1985). Screened Coulomb 
potentials where a distance dependent 
dielectric constant is used to model solvent 
effects describe the third term (Mehler, 
1991). The loss of conformational entropy 
due to binding is calculated in the fourth and 
fifth terms. The last term describes the 
solvation and desolvation effects as the 
protein or ligand atoms are fully hydrated or 
buried in the complex (Wesson, 1192). The 
docked complexes were then analyzed using 
a combination of AutoDockTools, chimera 
and pymol molecular visualization software. 
 
 
 
DGbind =DGvdw +DGhbond +DGelect + DGconf +DGtor +DGsolva
      
(1) 
 
Ki = e
DG
RT                                            (2) 
   
RESULTS  
 
Binding Energies 
In these simulations, 2 x 106 energy 
evaluations between each antimalarial drug 
and HTIM/PFTIM enzymes were screened 
to identify binding domains, important 
amino acid residues, binding energies and 
dissociation constants. For each docked 
system simulated, one hundred high affinity 
complexes were analyzed for binding 
domains and contact residues. All 
antimalarial drugs studied were successfully 
docked to the enzymes. The pairwise 
intramolecular, intermolecular and 
desolvation energies of the interaction 
between the ligands and enzymes was 
calculated using Equation 2. The binding 
energy difference between the ligand bound 
and unbound state was used to determine 
strength of interaction.  The complexes with 
more negative binding energy were selected 
for further analysis. Strong binding energies 
ranging from -4 to -12 kcal/mol were 
observed for HTIM and PFTIM interactions 
(Figure 2). Current antimalarial drugs like 
atovaquone, doxycycline, chloroquine, 
pentamidine, primaquine and mefloquine 
displayed a stronger affinity for PFTIM 
compared to HTIM.   
 
 
 
Figure 2: Relative binding energies between antimalarial drugs with HTIM (red) and PFTIM (blue). The 
estimated binding energies are computed using a combination of molecular mechanics forcefields and empirical 
parameterizations to estimate enthalpic and entropic contributions of interactions (equation 1).   
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Dissociation Constants 
The dissociation constants (Ki) 
computed with equation 2, describes how 
tightly bound the ligands are to HTIM and 
PFTIM. In addition to binding energies, this 
thermodynamic constant also has 
dimensions of concentration and describes 
the solution equilibrium between the 
enzyme receptors and the ligands (small 
organic molecules). Ki are also commonly 
used to rank the order strength of receptor 
ligand interactions. Nanomolar and 
submicromolar ranges are common for 
many drugs. The smaller the dissociation 
constant (nM or M) the more tightly bound 
the ligand is.  It is also the ligand 
concentration at which the active site, 
allosteric or other binding domains of a 
receptor like TIM is half filled.  A number 
of the ligands screened showed significant 
differences in dissociation constants 
between HTIM and PFTIM (Figure 3).  
Primaquine binds PFTIM with a Ki of 1.22 
M and 40.22 µM for HTIM.  This suggests 
that the binding between primaquine and 
PFTIM is about 33 times stronger than the 
interaction with HTIM. Similarly, 
mefloquine also shows an increased affinity 
to PFTIM by a factor of 24, while 
sulfanilamide an antibacterial drug with one 
benzene ring shows an increased affinity of 
a factor of 5. The dissociation constants 
suggest that PFTIM can potentially be a 
suitable target for selective inhibition by 
primaquine, mefloquine, chloroquine, and 
pentamidine. 
 
 
Figure 3: Dissociation constant between ligands with HTIM (red) and PFTIM (blue). The insert scales the Ki of 
ligands not visible on larger bar chart. Ki is computed from the estimated binding free energy of complex using 
equation 2. 
 
Many ligands have been used to curb the 
effects of malaria, targeting different 
receptors in the plasmodium parasite with 
different degrees of success (Table 1) 
(Harinasuta et al., 1985; Huy et al., 2002; 
Tan et al., 2011; Derbyshire et al., 2012). 
Their efficacy is however, hindered by 
parasitic resistance and side effects.  The 
indication from the micromolar dissociation 
constant in interactions with the glycolytic 
enzymes HTIM and PFTIM as potential 
molecular targets to fight malaria is 
interesting. 
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Table 1. Antimalarial Drugs and Ligand structures used in docking studies and associated side effects, 
target receptors and mutations responsible for resistance. (Bloland, 2001; Nixon, 2013; Hyde, 2007). 
Ligand Name Target receptor Side Effects Drug Resistance 
 
Pyrimethamine 
Dihydrofolate reductase  
(DHFR) 
Thymidylate synthetase  
(TS) 
Nausea, stomach 
cramps, vomiting, 
headache, itching,  
 
Resistance is due to 
point mutations e.g. 
C59R, I164L  
 
Proguanil 
Dihydrofolate reductase  
(DHFR) 
Thymidylate synthetase 
(TS) 
Agranulocytosis, 
megaloblastic and 
aplastic anemia, 
thrombocytopenia 
Resistance involve 
point mutations at 
S108N, N51I  
 
Quinine 
P-glycoprotein 
homologue 1 (Pgh1) 
Ringing in the ears, 
vomiting, diarrhea, 
nausea, blurred 
vision, cold sweats, 
convulsions, 
drowsiness 
Resistance due to 
mutation in pfmdr-1 
and pfcrt genes and 
corresponding 
protein target 
 
Chloroquine 
Chloroquine resistance 
transporter (CRT) 
 
Fever, chills, 
headache, flu-like 
symptoms 
Drug resistance due 
to mutation (K76T) 
in Pfmdr 1 and Pfcrt 
which encode CRT 
receptors 
 
Primaquine 
Unknown Nausea, stomach 
pain, vomiting, loss 
of appetite, 
abdominal cramps, 
heartburn 
Resistance and 
compliance issues 
 
Atovaquone 
Target the mammalian 
serotonin receptor 
 
Cytochrome b 
 
Maculopapular rash, 
nausea, diarrhoea 
and headache 
Drug resistance is 
given by mutation at 
Y268S/N/C 
 
Mefloquine 
P-glycoprotein 
homologue 1 (Pgh1) 
 
Multi drug resistance 1 
(MDR1) 
Headache, nausea, 
vomiting, hair loss, 
anorexia,  
Resistance is due to 
point mutations e.g. 
C59R, I164L  
 
Sulfanilamide 
Dihydropteroate 
synthetase 
 
Itching, anemia and 
swollen tongues 
Resistance is due to 
point mutations e.g. 
E540K, A437G 
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Binding Site and Complexes  
Complexes between primaquine, 
mefloquine, sulfanilamide and TIM were 
selected for further analysis. Two main 
binding domains were observed out of 100 
complexes analyzed for each screened 
ligand. For interactions involving PFTIM, 
the ligands preferred a binding site at the 
dimer interface of the enzyme.  There was a 
more even distribution between dimer 
interphase, active site proximity and other 
sites in the binding with HTIM (Figures 4 
and 5).  The favorable interactions observed 
at the dimer interface are mainly due to 
polar contacts with ligand atoms (Table 2). 
 
Table 2. Percentage of complexes formed in 
dimer interface and other binding domains 
on HTIM and PFTIM. 
 
 HTIM 
% 
PFTIM 
% 
Ligand Dimer Other Dimer Other 
Sulfanilamide 55 45 73 27 
 
Primaquine 34 64 72 28 
 
Mefloquine 60 40 68 32 
 
 
 
 
Figure 4: Surface diagram showing binding modes of 
primaquine (left), sulfanilamide (middle) and 
mefloquine (right) in interactions with HTIM. Ligand in 
red color. 
Figure 5: Surface diagram showing the dimer interphase 
binding modes of primaquine (left), sulfanilamide 
(middle) and mefloquine (right) in interactions with 
PFTIM. The ligand is buried in red. 
 
DISCUSSION  
 
AutoDock 4.2 was used as a 
preliminary tool to identify binding affinities 
and binding domains between a number of 
antimalarial therapeutic agents and the 
glycolytic enzyme TIM from human and 
Plasmodium falciparum cells. The major 
goal was to computationally identify ligands 
with the potential to selectively interact and 
hence inhibit glycolytic enzymes of 
plasmodium cells as opposed to human 
cells.  This is to determine whether 
glycolytic enzymes are suitable candidates 
and to continue the search for ligands that 
can replace current antimalarial agent whose 
efficiency is reduced by parasitic resistance. 
The data involving rigid enzyme 
targets reveal that primaquine prefers an 
allosteric binding site on the PFTIM. The 
dimer interphase of PFTIM has a collection  
 
 
 
 
of polar and hydrophobic amino acid 
residues (S45, V46, Y48, Q64, N65, F96) 
facing each other that may be an important 
binding domain for the ligands studied 
(Figure 6 and 7).  For example, 75 % of the 
high affinity complexes analyzed in PFTIM 
occur at the dimer interphase (Table 2). The 
complexes with HTIM were evenly 
distributed between the dimer interphase and 
a site proximal to the active site. This is 
despite the fact that the dimer interphase in 
both species have amino acids with similar 
physico-chemical properties and polarities. 
One possible reason for the difference in 
complex distribution with HTIM is the 
residue substitutions at position A46, I48, 
S96. The importance of these amino acid 
residue substitutions to the observed 
differences in ligand affinities was however, 
not explored further in this study using point 
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mutation studies. The polar contacts, which 
include hydrogen bonding and van der 
Waals interactions on both sides of the 
ligands, create a pocket that provides more 
favorable binding with PFTIM as opposed to 
HTIM (Figures 2, 6 and 7). The stronger 
affinity of these known ligands towards 
PFTIM as opposed to HTIM is mainly due 
to electrostatic forces. For example, PFTM 
is dimeric with an overall charge of -8e as 
opposed to -6e for HTIM. This difference in 
charge suggests that the amine-based ligands 
will show some selectivity.  The importance 
of electrostatic interaction in ligand binding 
selectivity has been well described in a 
number of studies (Astorga et al., 2012).  
For example quinolone-based ligands do not 
compete for the cofactor of binding site of 
alcohol dehydrogenase like glyceraldehyde 
phosphate dehydrogenase (GAPDH) due to 
unfavorable intrinsic electrostatics and 
hydrogen bonding (Waingeh et al., 2013).  
Similarly, the discrimination between K+ 
and Na+ by the narrowing potassium channel 
KscA is due to the intrinsic electrostatics 
and coordination between ions and carbonyl 
groups (Noskov et al., 2004).  In general a 
single molecular determinant cannot usually 
explain the high affinity or selectivity in 
functional protein complexes (Astorga et al, 
2012).  The ligands that show strongest 
affinity and improved selective binding to 
PFTIM over HTIM (Figure 8) possess key 
features. These ligands have a good 
combination of lipophilicity and polarity.  
The hydrophobic character is introduced by 
the presence of 2 or more phenyl rings and 
short alkyl chain. The lipophilic groups are 
flanked by hydrogen donors and acceptors 
creating a dipolar small organic molecule 
with ionizable features (Table 1).  This is the 
case for ligands with high Ki selectivity 
factors like chloroquine and primaquine. 
The Ki selectivity factor for Proguanil a 
mostly polar molecule is small (Figure 8). 
Azole-based ligands with lots of 
hydrophobic moieties or sulfanilamide fewer 
hydrophobic moieties (single phenyl ring) 
have smaller Ki selectivity factor.   
 
 
 
 
 
 
 
 
Figure 6: HTIM primaquine interaction region 
showing contact residues responsible for polar 
contacts. Contact residues show in ball and stick and 
the ligand in surface representation. 
 
 
 
Figure 7: PFTIM primaquine interaction region 
showing contact residues responsible for polar 
contacts. Contact residues show in ball and stick and 
the ligand in surface representation. 
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Table 3: Structure and binding energy of fine-tuned ligand analogues. The binding energies are 
color coded (PFTIM is blue and HTIM is red). 
A 
 
B 
 
C 
 
 
-5.72 kcal/mol 
-6.27 kcal/mol 
-6.66 kcal/mol 
-7.27 kcal/mol 
-8.11 kcal/mol 
-7.77 kcal/mol 
D 
 
E 
 
F 
 
-7.42 kcal/mol 
-7.45 kcal/mol 
-7.69 kcal/mol 
-5.79 kcal/mol 
-10.09 kcal/mol 
-8.91 kcal/mol 
Six new ligands (A, B, C, D, E and F) were 
designed and docked to HTIM and PFTIM 
(Table 3). The chemical modifications 
involved the increase of phenyl rings, 
substitution of fluorine for chlorine, and a 
change in position of polar fluorine atoms. 
The Ki data indicates that only compound E 
amongst the analogues improves the 
selective affinity for PFTIM over HTIM. 
The enhancement by a factor of 25 is better 
or on par with some current antimalarial 
agents (Figure 8). The enhanced selectivity 
factor for compound E is still however, 
lower than that of chloroquine and 
primaquine. 
 
CONCLUSIONS 
The data suggest that TIM is a potential 
candidate for development of antimalarial 
drugs. Some antimalarial agents likely 
interact with PFTIM and HTIM using 
different binding domains.  The dimer 
interface and other pocket close to the active 
site are the main pockets observed by the 
docking studies. Key residues at the dimer 
interphase (Y48, D49, V46, S45, E65, S211) 
form a tight pocket with favorable polar 
contacts. 75% of PFTIM ligand complexes 
preferred the dimer interphase suggesting a 
potential site for non-competitive inhibition. 
Ligand analogues can therefore be fine-
tuned to take advantage of differences in 
binding domains and residues between 
PFTIM and HTIM. 
 
 
Figure 8: Ki selectivity factor for ligand binding with 
HTIM and PFTIM.  
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In addition, the ligands do not seem to be 
competing for the active site of TIM but 
interact at proximal sites. Work is currently 
underway to determine how the flexibility 
and dynamic motions of both ligand and 
enzyme will affect the interactions using 
molecular dynamics simulations.   
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